These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26718162)

  • 1. KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management.
    Mallett A; Lee VW; Mai J; Lopez-Vargas P; Rangan GK
    Semin Nephrol; 2015 Nov; 35(6):582-589.e17. PubMed ID: 26718162
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel treatments of autosomal dominant polycystic kidney disease.
    Mahnensmith RL
    Clin J Am Soc Nephrol; 2014 May; 9(5):831-6. PubMed ID: 24721886
    [No Abstract]   [Full Text] [Related]  

  • 3. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autosomal dominant polycystic kidney disease.
    Simms RJ
    BMJ; 2016 Feb; 352():i679. PubMed ID: 26868522
    [No Abstract]   [Full Text] [Related]  

  • 5. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
    Rapoport J
    QJM; 2007 Jan; 100(1):1-9. PubMed ID: 17164322
    [No Abstract]   [Full Text] [Related]  

  • 6. [New strategy for the treatment of autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2015; 57(1):254-61. PubMed ID: 25735085
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
    Tkachenko O; Helal I; Shchekochikhin D; Schrier RW
    Curr Hypertens Rev; 2013 Feb; 9(1):12-20. PubMed ID: 23971639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
    Zafar I; Tao Y; Falk S; McFann K; Schrier RW; Edelstein CL
    Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.
    Rysz J; Gluba-Brzózka A; Franczyk B; Banach M; Bartnicki P
    Expert Opin Pharmacother; 2016 Oct; 17(15):2049-56. PubMed ID: 27650472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quest--halting the progression of autosomal dominant polycystic kidney disease.
    Ellison DH; Ingelfinger JR
    N Engl J Med; 2014 Dec; 371(24):2329-31. PubMed ID: 25399732
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal volume in children with ADPKD: size matters.
    Chapman AB; Guay-Woodford LM
    Clin J Am Soc Nephrol; 2009 Apr; 4(4):698-9. PubMed ID: 19339418
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel targets for the treatment of autosomal dominant polycystic kidney disease.
    Belibi FA; Edelstein CL
    Expert Opin Investig Drugs; 2010 Mar; 19(3):315-28. PubMed ID: 20141351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Levey AS; Stevens LA
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
    [No Abstract]   [Full Text] [Related]  

  • 15. New options in the treatment of autosomal dominant polycystic kidney disease.
    Kazancioglu R; Gursu M
    Ren Fail; 2015 May; 37(4):535-41. PubMed ID: 25682970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].
    Lacquaniti A
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 25083527
    [No Abstract]   [Full Text] [Related]  

  • 17. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Braun WE
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-8. PubMed ID: 21247326
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
    Ponticelli C; Locatelli F
    Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease.
    Kawada T
    Clin Exp Nephrol; 2016 Feb; 20(1):147-8. PubMed ID: 26070257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.